Multiresistente Keime - 500 Beiträge pro Seite
eröffnet am 29.01.20 18:11:51 von
neuester Beitrag 27.05.20 11:16:49 von
neuester Beitrag 27.05.20 11:16:49 von
Beiträge: 11
ID: 1.319.450
ID: 1.319.450
Aufrufe heute: 0
Gesamt: 380
Gesamt: 380
Aktive User: 0
ISIN: US86627R1023 · WKN: A14P7C
3,3800
USD
+1,20 %
+0,0400 USD
Letzter Kurs 19.09.20 NYSE
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3.000,00 | +74.900,00 | |
| 0,9300 | +54,46 | |
| 2,3300 | +35,61 | |
| 2,4700 | +33,51 | |
| 1,9100 | +29,93 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,3000 | -20,96 | |
| 2,5000 | -21,88 | |
| 1,4300 | -24,34 | |
| 2,2000 | -31,25 | |
| 2,0900 | -40,52 |
Feedback
Ein weiterer Titel, zu dem es noch keine Diskussion gibt.
Summit: Einer der wenigen Player gegen Multiresistente Keime
• Presentation: https://www.summitplc.com/app/uploads/2019/10/2019-RD-Day-Su…
• AGM: https://www.summitplc.com/app/uploads/2019/05/2019_Summit-Th…
• Float: 28 %. Issued share capital: 335,873,208. The percentage of Ordinary Shares not being held in public hands is 72%. Shares held in treasury: Nil Ordinary shares. There are no restrictions on the transfer of Ordinary Shares in the Company.
• Cash: A proposed fundraising of approximately $50 million through a subscription and placing of new ordinary shares and warrants to existing investors (the 'Fundraising') was announced on 6 December 2019. The Fundraising requires approval by shareholders at a general meeting of the Company to be held on 23 December 2019. If the Fundraising is completed, the net proceeds, together with the Company's existing cash resources and funding agreements, are expected to extend its cash runway to 31 January 2021. Cash and cash equivalents at 31 October 2019 of £13.6 million compared to £26.9 million at 31 January 2019. Cash position does not include the proposed Fundraising of approximately $50 million announced on 6 December 2019 (see Corporate Highlights above for further
• Burn Rate: Loss for the three months ended 31 October 2019 of £7.0 million compared to a loss of £8.1 million for the three months ended 31 October 2018. The Company today announces that it has changed its accounting reference date from 31 January to 31 December with immediate effect. Also circa 2,5 Mio Pfund pro Monat, also circa 24-32 M im Jahr
• Pipeline: Antibiotics (Urgent/High CDC/WHO Status), 1x Phase 3 against CDI, 3x Discovery Phase und 1x Preclinical Gonorrhea
Warum investieren?
- Gute Pipeline mit wichtigen Produkten
- Nach Finanzierungsrunde mit Cash ausgestattet
- Neuausrichtung nach DMD Failure
- Finanzierung nach Managementangaben bis 2021 gesichert
- Level der Finanzierungsrunde war bei 22 Pence, die amerkanischen ADS also circa bei 1,50 Dollar
Heute kleiner Crash auf 1,25 Dollar, also super Einsteigemöglichkeit!
Summit: Einer der wenigen Player gegen Multiresistente Keime
• Presentation: https://www.summitplc.com/app/uploads/2019/10/2019-RD-Day-Su…
• AGM: https://www.summitplc.com/app/uploads/2019/05/2019_Summit-Th…
• Float: 28 %. Issued share capital: 335,873,208. The percentage of Ordinary Shares not being held in public hands is 72%. Shares held in treasury: Nil Ordinary shares. There are no restrictions on the transfer of Ordinary Shares in the Company.
• Cash: A proposed fundraising of approximately $50 million through a subscription and placing of new ordinary shares and warrants to existing investors (the 'Fundraising') was announced on 6 December 2019. The Fundraising requires approval by shareholders at a general meeting of the Company to be held on 23 December 2019. If the Fundraising is completed, the net proceeds, together with the Company's existing cash resources and funding agreements, are expected to extend its cash runway to 31 January 2021. Cash and cash equivalents at 31 October 2019 of £13.6 million compared to £26.9 million at 31 January 2019. Cash position does not include the proposed Fundraising of approximately $50 million announced on 6 December 2019 (see Corporate Highlights above for further
• Burn Rate: Loss for the three months ended 31 October 2019 of £7.0 million compared to a loss of £8.1 million for the three months ended 31 October 2018. The Company today announces that it has changed its accounting reference date from 31 January to 31 December with immediate effect. Also circa 2,5 Mio Pfund pro Monat, also circa 24-32 M im Jahr
• Pipeline: Antibiotics (Urgent/High CDC/WHO Status), 1x Phase 3 against CDI, 3x Discovery Phase und 1x Preclinical Gonorrhea
Warum investieren?
- Gute Pipeline mit wichtigen Produkten
- Nach Finanzierungsrunde mit Cash ausgestattet
- Neuausrichtung nach DMD Failure
- Finanzierung nach Managementangaben bis 2021 gesichert
- Level der Finanzierungsrunde war bei 22 Pence, die amerkanischen ADS also circa bei 1,50 Dollar
Heute kleiner Crash auf 1,25 Dollar, also super Einsteigemöglichkeit!
Kurs klettert wieder langsam nach oben. Spezielle news zu dem Crash habe ich nicht gefunden
Über das Hauptprodukt
o We were also pleased to announce recently the proposed $50 million investment into Summit that will primarily be used to support the ongoing Phase 3 clinical programme and commercial preparatory activities for ridinilazole. We look forward to continuing to advance ridinilazole through our landmark Phase 3 clinical trials that remain on track to report results in the second half of 2021
o The Phase 3 clinical programme remains on track for expected reporting of top-line data in the second half of 2021. The trials had enrolled a total of 128 patients as at the end of November 2019 with over two thirds of the 300 planned clinical trials sites having been opened.
o Reported new Phase 2 clinical trial data that showed ridinilazole improved patients' quality of life compared to vancomycin, including statistically significant improvements in measurements of physical and mental health. Additional data from the Phase 2 clinical trial provided mechanistic insights into how ridinilazole preserved the diversity of the gut microbiome in patients with CDI to maintain the balance of the metabolome of active chemicals made or modified by gut bacteria that help prevent C. difficile recurrence. These new results were reported at the ID Week Conference held in Washington DC in October 2019.
o Commercial and medical affairs hires have been made in the United States to support work to prepare for a potential launch and to secure future market access for ridinilazole, if approved.
o We were also pleased to announce recently the proposed $50 million investment into Summit that will primarily be used to support the ongoing Phase 3 clinical programme and commercial preparatory activities for ridinilazole. We look forward to continuing to advance ridinilazole through our landmark Phase 3 clinical trials that remain on track to report results in the second half of 2021
o The Phase 3 clinical programme remains on track for expected reporting of top-line data in the second half of 2021. The trials had enrolled a total of 128 patients as at the end of November 2019 with over two thirds of the 300 planned clinical trials sites having been opened.
o Reported new Phase 2 clinical trial data that showed ridinilazole improved patients' quality of life compared to vancomycin, including statistically significant improvements in measurements of physical and mental health. Additional data from the Phase 2 clinical trial provided mechanistic insights into how ridinilazole preserved the diversity of the gut microbiome in patients with CDI to maintain the balance of the metabolome of active chemicals made or modified by gut bacteria that help prevent C. difficile recurrence. These new results were reported at the ID Week Conference held in Washington DC in October 2019.
o Commercial and medical affairs hires have been made in the United States to support work to prepare for a potential launch and to secure future market access for ridinilazole, if approved.
Bei 1,38 wieder. Wer mit bei 1,26 Dollar eingestiegen ist, hat 10 % mehr 
Unter 1,43 Dollar immer noch ein Schnäppchen.
Die neuen Aktien sind zu 1,43 Dollar (22 pence x5 = 1 ADR an der Nasdaq) rausgegeben worden
Siehe https://www.summitplc.com/app/uploads/2019/12/2019-RNS_42-Pr…
Die neuen Aktien sind zu 1,43 Dollar (22 pence x5 = 1 ADR an der Nasdaq) rausgegeben worden
Siehe https://www.summitplc.com/app/uploads/2019/12/2019-RNS_42-Pr…
Trading Spotlight
Letzter Post von mir für heute noch. Wer das letzte Dokument liest, sieht, dass der Großaktionär nach der KE 72 % halten wird. Geringer Float dadurch und deswegen möglicher Übernahmekandidat!
Hervorragend entwickelt. Schon über 33 % im Plus
Schade, dass sich keiner sonst interessiert
Schade, dass sich keiner sonst interessiert
Analystentargets übrigens bei mindestens 3 dollar
https://seekingalpha.com/news/3539283-summit-therapeutics-ea…
Afterhours up bei 1,75 Dollar. Steigt weiterhin
Afterhours up bei 1,75 Dollar. Steigt weiterhin
Oben verkauft, unten neu wieder eingekauft. Guter Einstiegszeitpunkt!
Will ja nicht angeben, aber mehr als verdoppelt
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +0,88 | |
| +3,31 | |
| -1,89 | |
| +1,18 | |
| -17,66 | |
| -30,76 | |
| 0,00 | |
| -3,51 | |
| +3,68 | |
| -1,96 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 212 | ||
| 116 | ||
| 100 | ||
| 85 | ||
| 77 | ||
| 45 | ||
| 44 | ||
| 41 | ||
| 31 | ||
| 31 |
